Access & Compounding

Discover how eligible Medicare Part D beneficiaries can access weight-loss medications like Wegovy and Zepbound for a $50 monthly copay through the new Medicare GLP-1 Bridge Program.

Medically authored by Joshua Silva, MD | Evidence-Based Weight Loss at Potere Health MD As of 2026, compounded semaglutide and tirzepatide are no longer broadly permitted in the United States. Following resolution of nationwide shortages, the FDA ended its temporary enforcement discretion, meaning these medications may now only be compounded under limited, legally defined circumstances .¹–³ On February 21, 2025 , the U.S. Food and Drug Administration formally declared the

Learn how the FDA Green List impacts compounded semaglutide and tirzepatide. Understand Import Alert 66-80, patient safety, and what it does not mean.